Also important to note here is that although DOACs affect LA tests, many patients with APS, and thus likely to be assessed for LA, may be transitioned away from DOACs and onto VKA and other therapies, according to preferred management strategies (eg, those at highest risk of thrombosis or triple positive for aPL) [35]. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.